Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT03895346 Completed - Aging Clinical Trials

Mental Training for Adults With Mild Cognitive Impairment

Start date: April 10, 2019
Phase: N/A
Study type: Interventional

This study aims to determine the feasibility and acceptability of conducting a larger randomized clinical trial to test whether individuals with MCI can benefit from mental training programs.

NCT ID: NCT03894709 Completed - Clinical trials for Cognitive Impairment

A Care Model for Elderly Hip-fractured Persons With Cognitive Impairment and Their Family Caregivers

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

This study aims to develop and examine an innovative family-centered intervention model for managing cognitive decline, improving postoperative recovery of hip-fractured patients with cognitive impairment, and enhancing family caregivers' competence in dementia care. This care model is theoretically underpinned by: (a) the Progressively Lowered Stress Threshold Model, a component of Lawton's ecological model of aging, and (b) the concept of partnership with family caregivers to strengthen their competence in providing care. Training are provided to family caregivers to enhance their competence in caring for hip-fractured patients with cognitive impairment. The effectiveness of the care model has been evaluated in a randomized controlled trial. The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital. A protocol of the family-centered care model was developed, and the research nurses were trained to provide the interventions. A checklist, consisting of postoperative care, rehabilitation exercises, nutritional health teaching, environmental modification suggestions, delirium care, and care issues for elders with cognitive impairment, as well as management of behavioral problems, was also developed and are recorded by the research nurses. This report is based on data collected from 149 dyads of participants who were recruited by September 2018 and randomly assigned to either an experimental group (n=73) or a control group (n=76). No significant differences are found between experimental and control group in their demographic and clinical variables including age, gender, diagnosis, surgery type, the length of hospital stay, the cognitive functioning, marital status, and educational level, as well as the age and gender of family caregivers. The refusal rate this year is 73.6%. The main reasons for caregivers not participating are not needed and too busy or afraid of being interrupted. No significant differences are found in demographic variables (ie, age, gender, diagnosis, surgery method, and length of hospital stay) between those who participated and those who refused. Causes of the attrition includes that participants refused to participate any more (n=25), died (n=12), moved to another location (n=6), and loss of contact (n=3). Older persons who quit participating in the study are more younger (p=.021) and more are diagnosed with inter-/sub-trochanteric fracture (p=.015) as well as more are receiving internal fixation (p=.029). Outcome variables including patients' cognitive function, clinical measures, self-care ability, family caregivers' competence and preparedness, health service utilization, quality of life, and cost of care. In addition to the clinical effectiveness of the family-centered care model will be evaluated by hierarchical linear models at the end of this study.

NCT ID: NCT03892512 Recruiting - Clinical trials for Cognitive Dysfunction

Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction

Start date: April 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Dexmedetomidine is a highly selective α2adrenoceptor agonist recently introduced to anesthesia that produces dose dependent sedation, anxiolysis, and analgesia (involving spinal and supraspinal sites) without respiratory depression. From a pharmacokinetic perspective,dexmedetomidine has a half life of nearly 2 hours, duration of action of nearly 4 hour, and thus, a side effect profile that is shorter in duration than clonidine. Esmolol is a cardioselective beta₁ receptor blocker with rapid onset, a very short duration of action (elimination half-life is approximately 9 minutes) , and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages

NCT ID: NCT03891277 Recruiting - Iron-deficiency Clinical Trials

Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)

FAVORITE
Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The prevalence of Vascular Cognitive Impairment(VCI) is high in patients after ischemic stroke or transient ischemic attack(TIA) . Effective therapy for the prevention of VCI remains limited. The primary purpose of this study is to evaluate the efficacy and safety of Ferrous iron versus placebo on the prevention of vascular cognitive impairment among patients with ischemic stroke/TIA complicated with Hemoglobin deficiency.

NCT ID: NCT03889327 Completed - Multiple Sclerosis Clinical Trials

Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis

Start date: March 26, 2018
Phase: N/A
Study type: Interventional

Multiple sclerosis (MS) is among the most prevalent autoimmune diseases among young and middle-aged adults. Up to 65% of MS patients experience objective cognitive impairment including problems with information processing speed, memory, and executive functioning. However, patients commonly overestimate the extent of their cognitive dysfunction which can result in inaccurate perceptions of their true cognitive abilities. Exaggerated perceptions of cognitive impairment are predictive of future decline and associated with depression, anxiety, and reduced quality of life. Despite this, no study has examined an intervention aimed at changing misperceptions related to perceived cognitive impairment in MS when objective measures are incongruent with self-reported cognitive symptoms. The purpose of the present study is to develop and pilot a brief intervention for MS patients who perceive cognitive impairment, but perform in the normal or expected range on objective measures of cognition.

NCT ID: NCT03887923 Completed - Alzheimer Disease Clinical Trials

Vestibular Physical Therapy for People With Alzheimer Disease

VPT in AD
Start date: May 10, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the tolerability and preliminary efficacy of an 8-week home-based vestibular physical therapy program in people with cognitive impairment.

NCT ID: NCT03887741 Enrolling by invitation - Clinical trials for Mild Cognitive Impairment

Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Start date: September 15, 2021
Phase: Phase 1
Study type: Interventional

Determine safety of plasma infusion or exchange in APOE 44 patients.

NCT ID: NCT03886675 Recruiting - Stroke Clinical Trials

Intervention With Cerebral Embolic Protection in TEVAR: Gaseous Protection

INTERCEPT:GP
Start date: November 14, 2022
Phase: N/A
Study type: Interventional

Vascular brain infarction (VBI) occurs in 67% of patients undergoing TEVAR. Overt stroke occurs in 13% of these patients and 88% of patients suffer from neurocognitive impairment. Cerebral air embolisation during the stent-graft deployment phase of TEVAR may be a cause of VBI. Standard treatment to de-air stent-grafts is through the use of a saline flush. This study aims to investigate whether carbon-dioxide or saline is the better fluid to de-air TEVAR stent-grafts prior to insertion in to the patient and compare VBI rate in the carbon-dioxide group and saline group.

NCT ID: NCT03883633 Completed - Alzheimer Disease Clinical Trials

Reversal of Cognitive Decline (ReCODE) Study

RECODE
Start date: June 30, 2019
Phase:
Study type: Observational

Prospective study on patients enrolled in the ReCODE treatment protocol

NCT ID: NCT03883308 Completed - Clinical trials for Mild Cognitive Impairment

The Influence of Multi-domain Cognitive Training on Large-scale Structural and Functional Brain Networks in MCI

Start date: October 30, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to integrate advanced computational techniques and multimodal neuroimaging methods to examine the potential effects of long-term, multi-domain, online, computerized cognitive training on large-scale structural and functional brain networks in older adults with mild cognitive impairment (MCI).